Bibliographic citations
Camacho, C., (2016). Hiperglicemia inducida por betabloqueadores en pacientes hipertensos del hospital I Florencia de Mora - Essalud. [Tesis, Universidad Privada Antenor Orrego - UPAO]. https://hdl.handle.net/20.500.12759/3862
Camacho, C., Hiperglicemia inducida por betabloqueadores en pacientes hipertensos del hospital I Florencia de Mora - Essalud. [Tesis]. : Universidad Privada Antenor Orrego - UPAO; 2016. https://hdl.handle.net/20.500.12759/3862
@misc{renati/376717,
title = "Hiperglicemia inducida por betabloqueadores en pacientes hipertensos del hospital I Florencia de Mora - Essalud.",
author = "Camacho Narro, Carolina",
publisher = "Universidad Privada Antenor Orrego - UPAO",
year = "2016"
}
Hypertension is a disease with high incidence worldwide and in Peru. Due to its own pathophysiology or treatment, it increases the risk of triggering other comorbidities such as diabetes mellitus. Objective: To determine whether the use of beta-blockers induce hyperglycemia in hypertensive patients. Materials and methods: A retrospective cohort study was carried out in 108 patients at Florencia de Mora Essalud Hospital, 36 receiving non-diuretic antihypertensive (ACE inhibitors, ARBs, CA) in association with atenolol and 72 received non diuretic antihypertensive in monotherapy Results: The mean fasten glycemia was 89.08 mg/dl at the beginning in the atenolol group and 87.04 mg/dl in the other drugs group (p>0.05); after six months or more with the treatment the levels were 99.9 mg/dl and 92.85 mg/dl respectively (p<0.05). Glucose levels rises in 10.83 mg/dl in atenolol group and 5.5 mg/dl in other drugs group (p<0.05) The incidence of hyperglycemia was 47.2% in the atenolol group and 15.3% in the other group which generated a RR = 3.091, 95% CI [1.623 to 5.887] p <0.05. Glucose level did not reached diabetes range. Conclusion: The use of beta-blockers like atenolol after six months or more in arterial hypertension treatment increases the risk of hyperglycemia.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.